Clinical Trial Update: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical study evaluating Pexa-Vec in combination with anti-PD-L1 antibody ZKAB001 for metastatic melanoma after failed first-line treatment is in e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) (Pexa-Vec)
• ZKAB001 (PD-L1 antibody)

Snippet

Sponsor: Lee's Pharmaceutical Limited | Conditions: Local Progression or Metastatic Melanoma With Failed First-line Treatment | Phase 1, Phase 2 | Status: UNKNOWN